News and Press Releases
Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...
Category: BioManufacturing, Clinical Trials, Other, Pharmaceutical
Posted: December 4, 2025
AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development
New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules 2 December 2025 -- Washington State, US -- As drug developers face increasing pressure to lower...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows
Collaboration aims to equip users with complete NGS solution from sample to answer 12 November 2025 -- Colorado and Indiana, US -- Danaher companies Integrated DNA Technologies (IDT), a global leader in...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 12, 2025
EpiCypher Launches Fiber-seq Kit to Democratize Single-Molecule Chromatin Mapping
11 November 2025 -- North Carolina, US -- EpiCypher, a leader in chromatin biology and epigenetics, today announced the launch of its CUTANA Fiber-seq Kit and the exclusive licensing of...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2025
Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates
Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2025
Synthego Launches High-Performance Molecular Reagents for Clinical and Molecular Diagnostics
10 November 2025 -- California, US -- Synthego, a leading provider of CRISPR solutions, has announced a strategic expansion of its product offerings with the launch of a new portfolio of...
Category: Biotechnology, Other, Pharmaceutical
Posted: November 10, 2025
Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8 HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 6, 2025
Wakam and the FondaMental Foundation create the Precision Mind Award to support Franco-British research on biomarkers in psychiatry
4 November 2025 -- Paris, France -- Following the signing of the Franco-British consortium agreement on biomarkers in psychiatry at the French Embassy in London on 27th October 2025, Wakam...
Category: Drug Discovery, Other, Pharmaceutical
Posted: November 4, 2025
Hôpital Albert Chenevier, Pôle de Psychiatrie 40, rue de Mesly 94000 Créteil, France
Ryvu Therapeutics Announces Three Abstracts on Romaciclib (RVU120) and One Abstract on Dapolsertib (MEN1703) at the 2025 ASH Annual Meeting
Romaciclib continues to show efficacy in AML: Data from the Phase II RIVER-81 trial suggest that romaciclib restores sensitivity to venetoclax in resistant AML, inducing complete remissions with a favorable safety profile Clinical activity in myelofibrosis (MF): Interim results from the Phase II POTAMI-61 study indicate clinically meaningful spleen volume...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 3, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
Ryvu Therapeutics Presents RVU305 (PRMT5i) and ONCO Prime Platform Data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates strong and selective antitumor efficacy in MTAP-deleted glioblastoma models, with confirmed brain exposure and a favorable safety profile supporting IND/CTA-enabling studies...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025
Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges 27 October 2025 -- Frankfurt, Germany -- Thermo Fisher Scientific...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025
Naobios and Tokyo Metropolitan Institute of Medical Science partner to develop new live-attenuated vaccine against mpox
Partnership aims to commercialize new mpox vaccine - with higher level of safety - by 2027 23 October 2025 -- Nantes, France, and Tokyo, Japan -- Naobios, a CDMO (Contract Development...
Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 23, 2025
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 23, 2025
Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar FYB203 under the brand name Baiama across Key European Markets including its Home Market France
23 October 2025 -- Nice, France -- Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into...
Category: Logistics, Other, Pharmaceutical
Posted: October 23, 2025
